Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036073 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL524835 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL3426738 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL3976225 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL525558 | 1.00 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL25144 | 0.99 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL97613 | 0.95 | KMT2A (0.50) | KMT2ATLR2FABP5FABP7CA1 | |
| Succinic Acid SCHEMBL28760118 | 0.94 | KMT2A (0.50) | KMT2ATLR2FABP5FABP7HDAC1 | |
| Tetrahydrofuran SCHEMBL28301142 | 0.91 | KMT2A (0.43) | KMT2ATLR2FABP5FABP7HDAC1 | |
| SCHEMBL31658990 | 0.90 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2026-01-08 | — | — | US | disclosed |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4562099-A1 | CA-IX TARGETING FLUORESCENT PROBES | Bracco Imaging SPA (IT) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562100-A2 | CA-IX TARGETING FLUORESCENT PROBES | Bracco Imaging SPA (IT) | 2025-06-04 | — | — | EP | disclosed |
| US-7118737-B2 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1318827-A4 | POLYMER-MODIFIED SYNTHETIC PROTEINS | GRYPHON THERAPEUTICS INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050089970-A1 | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use | AMYLIN PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2004094465-A2 | SYNTHETIC MOLECULES THAT MIMIC CHEMOKINES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS OFFICE OF TECHNOLOGY MANAGEMENT UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040115774-A1 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| CN-1460023-A | Polymer modified bioactive synthetic chemokines and methods of production and use | GRYPHON TREAT CO (US) | 2003-12-03 | — | — | CN | disclosed |
| EP-1318827-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | Gryphon Therapeutics, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002020033-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA12, CA1 | KMT2A 2160/4885TLR2 1936/4885FABP5 1238/4885 |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | LHCGR, GNRHR, SSTR1 | KMT2A 2359/4885TLR2 1885/4885FABP5 1023/4885 |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FGFR1 | KMT2A 3796/4885TLR2 2129/4885FABP5 178/4885 |
| US-20050089970-A1 | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use | CCL11, CCL2, ACKR3 | KMT2A 4049/4885TLR2 666/4885FABP5 2016/4885 |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA4, CA7 | KMT2A 2697/4885TLR2 4631/4885FABP5 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.